NASDAQ:CRBP   CORBUS PHARMACEUTICALS HOLDINGS IN
At only $450mcap is Corbus Pharmaceuticals undervalued?

1) Corbus is different from other cannabis stocks as they are designing therapies around marijuana to treat fibrotic diseases. If these therapies work, some analysts put the value of their potential sales at $2bn a year.

2) At a small marketcap of $450m, Corbus could be a real untouched gem in the cannabis industry, compared to its competitors with $4bn+ marketcap.

3) After an agreement with Japananese Kaken Pharmaceutical , Corbus is on the way to receive an additional $173m upon achievement of various milestones
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
HE עברית
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out